Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01270880 · ClinicalTrials.gov registry record · Phase 2
Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
A Phase 2 study, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT01270880 is a Phase 2 study that has completed, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 18 participants.
The verdict
NCT01270880, a Phase 2 study, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
Hsp90 inhibitor STA-9090 may stop the growth of tumor cells by blocking some of the proteins needed for cell growth. This phase II trial is studying how well Hsp90 inhibitor STA-9090 works in treating patients with metastatic hormone-resistant prostate cancer previously treated with docetaxel-based chemotherapy
Interventions
- OTHER laboratory biomarker analysis
- GENETIC polymerase chain reaction
- GENETIC RNA analysis
- OTHER enzyme-linked immunosorbent assay
- DRUG Hsp90 inhibitor STA-9090
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2011-01 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01270880
The ClinicalTrials.gov registry entry for NCT01270880 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01270880 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01270880 about?
NCT01270880 is a clinical study titled "Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy". Hsp90 inhibitor STA-9090 may stop the growth of tumor cells by blocking some of the proteins needed for cell growth. This phase II trial is studying how well Hsp90 inhibitor STA-9090 works in treating patients with metastatic hormone-resistant prostate cancer previously treated with docetaxel-based ...
What is the current status of trial NCT01270880?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2011-01. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01270880?
The interventions under investigation include: laboratory biomarker analysis (OTHER), polymerase chain reaction (GENETIC), RNA analysis (GENETIC), enzyme-linked immunosorbent assay (OTHER), Hsp90 inhibitor STA-9090 (DRUG).
Who is sponsoring clinical trial NCT01270880?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.